指南与共识腹部CTMRUSDSA

日本肝癌协会肝细胞癌转化与新辅助治疗定义共识

Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association.
指南 / 共识 · Liver Cancer · 2026-06-09

日本肝癌协会成立工作组,针对晚期肝细胞癌系统治疗联合局部治疗的转化治疗术语缺乏统一定义的问题,制定共识性定义。共识明确了转化手术、新辅助治疗、消融作为转化治疗的定义,并提出功能性转化与肿瘤学转化两个核心概念。共识建议不应将TACE归为转化治疗,因其根治潜力有限。

要点

  • 转化治疗分为功能性转化与肿瘤学转化两个维度评估。
  • TACE因根治潜力有限,不应归类为转化治疗。
  • 报告转化治疗后影像时,应区分功能性与肿瘤学转化标准。

核心结论

  • 共识提出了转化手术、新辅助治疗及消融作为转化治疗的标准化定义,并引入功能性转化与肿瘤学转化两个关键概念。
  • 建议不将TACE归类为转化治疗,因其根治潜力有限。

研究设计与样本

  • 制定机构为日本肝癌协会,设立共识性「转化定义工作组」作为官方项目。
  • 工作组由肝胆外科、肝病学、放射学专家组成,设报告人负责起草与修订定义。
  • 采用共识制定方法,未报告具体证据分级标准。

诊断标准与关键数值

  • 功能性转化基于肝脏功能储备进行评估。
  • 肿瘤学转化基于肿瘤状态进行评估。
  • 消融可作为转化治疗的一种形式。

临床应用与阅片要点

  • 临床研究比较转化治疗结局时,应采用共识定义以增强可比性。
  • 影像评估转化治疗时,需分别报告功能性与肿瘤学转化状态。
  • 采用共识定义有助于为指南制定和未来临床研究提供共同框架。

局限性

  • 共识指出相关定义尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

With the advent of novel systemic therapies that provide high response rates, such as lenvatinib, atezolizumab-bevacizumab, durvalumab-tremelimumab, and nivolumab-ipilimumab, treatment strategies for patients with advanced hepatocellular carcinoma (HCC) have markedly evolved, and discussions on conversion therapy - which, broadly speaking, combines these systemic therapies with locoregional modalities - have become commonplace. However, the term "conversion therapy" has not yet been clearly defined, making it difficult to compare treatment outcomes among studies. To address this issue, the Japan Liver Cancer Association established a consensus-based "Working Group on the Definition of Conversion" as an official project of the association. The working group comprised experts in hepatobiliary surgery, hepatology, and radiology, with a rapporteur responsible for drafting and revising the definitions. The group proposed standardized definitions for "conversion surgery," "neoadjuvant therapy," and "ablation as conversion therapy," while recommending that transcatheter arterial chemoembolization should not be classified as conversion therapy due to its limited curative potential. The definitions also introduced two key concepts: functional conversion (based on the hepatic functional reserve) and oncological conversion (based on the tumor status). Adoption of these definitions is expected to facilitate appropriate evaluation of pretreatments and outcomes of conversion therapy. Ultimately, these efforts are expected to contribute to refining clinical decision-making, providing a common framework for guideline development and future clinical studies, and improving the outcomes of multidisciplinary treatments for advanced HCC; however, further validation is required.

来源:Liver Cancer,查看原文。版权归原作者所有。

引用

  1. Ichida, Tateishi, Hatano, et al. Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association. Liver Cancer. 2026. PMID: 42524660. doi:10.1159/000552928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。